S 483 · in committee · significant
Responsibility in Drug Advertising Act of 2025
- healthcare
What this bill does
- This bill bans drug makers from advertising new medications directly to consumers for three years after FDA approval.
- It affects pharmaceutical companies and patients who might see drug ads on social media or other channels.
- The FDA can grant early waivers in year three if ads benefit public health, or extend bans if safety issues emerge.
Generated by claude-haiku-4-5
Community Threads
Started by Cosponsor
- 01
How might a three-year advertising ban on new drugs affect patients' awareness of treatment options that could help their specific conditions?
- 02
What evidence suggests that direct-to-consumer drug advertising after FDA approval creates public health problems the ban would address?
- 03
Should the FDA's waiver authority depend on different criteria for rare diseases versus common conditions with existing treatments?
Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.
Sponsor · I-ME
Angus S. King Jr.
Citizen cosponsors
0
In Congress
2/ 100
Senators cosponsoring
Introduced 2025-02-06
Joining the bill
Legislative timeline
2025-02-06 · senate · IntroReferral
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
2025-02-06 · IntroReferral
Introduced in Senate
Citizen comments
Sign in to comment on this bill.
No comments yet — be the first.